Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical …
…, MS Ahluwalia, K Fink, F Di Meco, F Lieberman… - Jama, 2017 - jamanetwork.com
Importance Tumor-treating fields (TTFields) is an antimitotic treatment modality that
interferes with glioblastoma cell division and organelle assembly by delivering low-intensity …
interferes with glioblastoma cell division and organelle assembly by delivering low-intensity …
Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial
…, DM Steinberg, SA Toms, LP Taylor, F Lieberman… - Jama, 2015 - jamanetwork.com
Importance Glioblastoma is the most devastating primary malignancy of the central nervous
system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (…
system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (…
[HTML][HTML] Induction of CD8+ T-cell responses against novel glioma–associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic …
…, IF Pollack, AM Salazar, FS Lieberman - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
Purpose A phase I/II trial was performed to evaluate the safety and immunogenicity of a novel
vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic peptides …
vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic peptides …
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas
…, LM DeAngelis, HI Robins, FS Lieberman… - Neuro …, 2008 - academic.oup.com
The North American Brain Tumor Consortium (NABTC) uses 6-month progression-free survival
(6moPFS) as the efficacy end point of therapy trials for adult patients with recurrent high-…
(6moPFS) as the efficacy end point of therapy trials for adult patients with recurrent high-…
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy
…, RL Schilsky, S Bain, EJ Berghorn, F Lieberman - Seminars in …, 2006 - Elsevier
Peripheral neuropathy induced by cancer chemotherapy represents a large unmet need for
patients due to the absence of treatment that can prevent or mitigate this common clinical …
patients due to the absence of treatment that can prevent or mitigate this common clinical …
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
…, S Chang, L Junck, D Schiff, F Lieberman… - Clinical Cancer …, 2006 - AACR
Purpose: Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics
of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-…
of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-…
Differential sensitivity of glioma-versus lung cancer–specific EGFR mutations to EGFR kinase inhibitors
Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs
through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR …
through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR …
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
…, M Mehta, LM DeAngelis, F Lieberman… - Neuro …, 2010 - academic.oup.com
Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent anaplastic
glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) were …
glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) were …
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods
…, MJ Oborski, M Hwang, FS Lieberman… - Cancer management …, 2014 - Taylor & Francis
Malignant gliomas consist of glioblastomas, anaplastic astrocytomas, anaplastic
oligodendrogliomas and anaplastic oligoastrocytomas, and some less common tumors such as …
oligodendrogliomas and anaplastic oligoastrocytomas, and some less common tumors such as …
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01 …
…, MR Rossi, JR Razier, LE Abrey, FS Lieberman… - Clinical Cancer …, 2005 - AACR
Purpose: We investigated the molecular effect of the epidermal growth factor receptor (EGFR)
inhibitors erlotinib and gefitinib in vivo on all available tumors from patients treated on …
inhibitors erlotinib and gefitinib in vivo on all available tumors from patients treated on …